Clinical trials: Acute Schizophrenia
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia
The purpose of this study is to determine the safety and efficacy of iloperidone compared to placebo and an active comparator in the treatment of patients with schizophrenia in acute exacerbation.
- Trial name
- NCT00254202
- Testing
- Iloperidone, Ziprasidone
- Where
- 42 sites in United States, India
- Volunteers
- 593 people
- Sponsor
- Vanda Pharmaceuticals
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00151424
- Testing
- asenapine, Olanzapine
- Volunteers
- 277 people
- Sponsor
- Organon and Co
Schizophrenia
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
- Trial name
- NCT03345979
- Testing
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
- Trial name
- GUEST (NCT00988728)
- Testing
- SCH 900435 (Org 25935), Olanzapine
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Efficacy and Safety of Asenapine With Placebo and Olanzapine (41021)(P05933)
Schizophrenia is a brain disease. The primary features of schizophrenia are characterized by Positive symptoms (symptoms that should not be there, inability to think clearly, to distinguish reality from fantasy i.e., hearing…
- Trial name
- NCT00156117
- Testing
- asenapine, olanzapine
- Volunteers
- 417 people
- Sponsor
- Organon and Co
Acute Schizophrenia
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of brexpiprazole compared with placebo as maintenance treatment in adults with schizophrenia.
- Trial name
- EQUATOR (NCT01668797)
- Testing
- Brexpiprazole
- Where
- 49 sites in United States, Colombia and 6 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Schizophrenia
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.
- Trial name
- VECTOR (NCT01396421)
- Testing
- OPC-34712 [Brexpiprazole] High Dose, Experimental: OPC-34712 [Brexpiprazole] Middle Dose, Experimental: OPC-34712 [Brexpiprazole] Low Dose
- Where
- 60 sites in United States, Canada and 7 more
- Volunteers
- 636 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Mania
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and…
- Conditions
- Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
- Trial name
- NCT00644800
- Testing
- Ziprasidone
- Where
- 8 sites in Brazil
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia
This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia.
- Trial name
- NCT00768612
- Testing
- SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with…
- Trial name
- NCT07038876
- Testing
- ML-007C-MA BID, ML-007C-MA QD
- Where
- 24 sites in United States
- Volunteers
- 307 people
- Sponsor
- MapLight Therapeutics
Schizophrenia
A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia
RECONNECT-S ALPHA is a multicentre study to observe the management of schizophrenic patients who are hospitalized due to an acutely agitated psychotic episode.
- Trial name
- RECONNECT-S (NCT01394601)
- Where
- 8 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Schizophrenia
Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia
The primary purpose of this study is to evaluate the overall efficacy of aripiprazole intramuscular (IM) depot as acute treatment in subjects with schizophrenia.
- Trial name
- NCT01663532
- Testing
- Aripiprazole IM Depot
- Where
- 49 sites in United States, Croatia and 1 more
- Volunteers
- 340 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Olanzapine in Patients With Schizophrenia
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than…
- Trial name
- NCT00970281
- Testing
- Rapid-Acting Intramuscular Olanzapine
- Where
- 11 sites in Japan
- Volunteers
- 91 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104766
- Testing
- Cariprazine, Aripiprazole
- Where
- 58 sites in United States, Romania and 2 more
- Volunteers
- 617 people
- Sponsor
- Forest Laboratories
Schizophrenia
Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia
Observational, non-comparative, epidemiological study to collect and analyse real life data on schizophrenic patients receiving quetiapine according to the standard medical practice in Croatia.
- Trial name
- NCT00981123
- Where
- 18 sites in Croatia
- Volunteers
- 500 people
- Sponsor
- AstraZeneca